Suggested Remit: To appraise the clinical and cost effectiveness of glasdegib within its marketing authorisation for untreated acute myeloid leukaemia.
NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence submission.
Status Discontinued
Process STA 2018
ID number 1334

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Pfizer (Glasdegib)
Others Department of Health and Social Care
  NHS England
  NHS North West Surrey CCG
  NHS Thanet CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Chronic Lymphocytic Leukaemia Forum
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (cytarabine)
  Celgene (azacitidine)
  Hospira UK (cytarabine)
  Jazz Pharmaceuticals UK (cytarabine, daunorubicin)
  Napp Pharmaceuticals (cytarabine)
  Novartis (midostaurin)
  Pfizer (cytarabine, gemtuzumab ozogamicin)
  Zentiva (daunorubicin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Hospital Information Services – Jehovah’s Witnesses
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Blood and Transplant
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
02 September 2020 Discontinued. NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence submission.
30 July 2020 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
30 September 2019 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of glasdegib for treating acute myeloid leukaemia who are not fit for intensive chemotherapy. Following on from advice received from the company, the timelines are currently to be confirmed pending data for glasdegib from future ongoing trials in this indication. Therefore, we are suspending this appraisal. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if or when the situation changes.
04 September 2019 Invitation to participate
06 June 2019 - 04 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2017 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance